Oncolytics Reports Overall, KRAS-Mutated Patient Data from US Randomized Phase 2 Pancreatic Cancer Study

By: via Benzinga
Oncolytics Biotech^® Inc. ("Oncolytics") (NASDAQ: ONCY) today announced overall and KRAS-mutated patient data from a two-arm ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.